Results 121 to 130 of about 10,308 (152)

Imatinib Mesylate

2009
Imatinib mesylate (Gleevec, Glivec [Novartis, Basel, Switzerland], formerly referred to as STI571 or CGP57148B) represents the paradigm of a new class of anticancer agents, so-called small molecules. They have a high selectivity against a specific molecular target known to be the cause for the establishment and maintenance of the malignant phenotype ...
openaire   +6 more sources

An evaluation of the cardiotoxicity of imatinib mesylate

Leukemia Research, 2008
We studied 103 consecutive patients with chronic myeloid leukaemia on treatment with imatinib (IM) and 57 patients with chronic myeloproliferative disorders not treated with IM in order to evaluate its cardiotoxicity. There was no statistical difference regarding cardiac symptoms and signs, BNP levels and echocardiographic measurements for IM and ...
Antonio Luiz, Ribeiro, Milena Soriano, Marcolino, Henrique N S, Bittencourt, Márcia M, Barbosa, Maria do Carmo P, Nunes, Vitor Fonseca, Xavier, Nelma C D, Clementino   +6 more
openaire   +2 more sources

Role of Imatinib Mesylate in Osteoblastogenesis.

Blood, 2007
Abstract Imatinib mesylate (IM), a tyrosine kinase inhibitor, currently used in chronic myeloid leukaemia (CML) may also affect the growth of other cellular systems besides CML cells. It has been reported that IM may affect bone tissue remodeling mainly by an inhibitory activity on osteoclastogenesis.
D. TIBULLO, C. GIALLONGO, P. LA CAVA, S. BERRETTA, F. STAGNO, A. CHIARENZA, G. A. PALUMBO, DI RAIMONDO, FRANCESCO   +7 more
openaire   +2 more sources

Effects of imatinib mesylate in osteoblastogenesis

Experimental Hematology, 2009
Imatinib mesylate (IM), a tyrosine kinase inhibitor currently used in chronic myeloid leukemia (CML), may also affect the growth of other cellular systems besides CML cells. Because it has been reported that IM may affect bone tissue remodeling, we evaluated the effects of IM on osteoblastic differentiation of human bone marrow mesenchymal stem cells ...
TIBULLO D, GIALLONGO C, LA CAVA P, BERRETTA S, STAGNO F, CHIARENZA A, CONTICELLO C, PALUMBO GA, DI RAIMONDO, FRANCESCO   +8 more
openaire   +3 more sources

Imatinib mesylate

American Journal of Health-System Pharmacy, 2001
openaire   +3 more sources

Discontinuation of Imatinib May Be Possible in Chronic Myelogenous Leukemia

Ca-A Cancer Journal for Clinicians, 2011
Mary Kay Barton
exaly  

Two-Stage Phase II Study of Imatinib Mesylate in Subjects With Refractory or Relapsing Neuroblastoma

Annals of Oncology, 2013
Marta Podda, Alberto Garaventa, Roberto Luksch   +2 more
exaly  

Adjuvant Imatinib Mesylate After Resection of Localised, Primary Gastrointestinal Stromal Tumour: A Randomised, Double-Blind, Placebo-Controlled Trial

Lancet, The, 2009
Margaret von Mehren, Shreyaskumar Patel, Karla V Ballman   +2 more
exaly  

Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors

New England Journal of Medicine, 2002
Margaret von Mehren, Renaud Capdeville, Samuel Singer   +2 more
exaly  

Imatinib Mesylate

2011
openaire   +2 more sources